KPMG Corporate Finance acted as exclusive financial advisor to RxMx
RxMx was established in 2013 by a team of doctors focused on modernizing and enhancing the effectiveness and safety of prescribing and monitoring specialty medicines. The Company is based in Sydney and has expanded with offices in New York and Berlin. It works with many of the top ten pharma companies around the world.
RxMx CEO George Hunnewell said: "We're thrilled to be working with a world-class investment firm who will bring new opportunities that we'll be able to leverage through this agreement. We look forward to working together to grow the company – there's an exciting new chapter ahead for RxMx."
Mark Summerhayes, Co-Managing Director at Pemba, said: "RxMx is Pemba's 20th technology investment in the last 5 years. As a clear global leader in patient monitoring SaaS for specialty medicine it's an exciting company to back. It's highly innovative and importantly, it has also established and fast-growing relationships with big pharma globally. "The RxMx team was looking for a partner to help drive international expansion and Pemba brings deep tech investing experience, growth capital, M&A know-how and global networks to help to accelerate growth.
"We are all especially pleased to be involved in developing technologies that are enabling life changing therapies to be brought safely to patients with serious chronic diseases," Mr. Summerhayes said.
In today’s market, you need an advisor with objective insight at every step of the transaction process. We work with you throughout the full deal cycle to create value and successfully execute your deal strategy.
KPMG Corporate Finance LLC
The global Corporate Finance practice of KPMG International’s network of independent member firms was ranked #1 as the top M&A middle-market adviser globally by Refinitiv, based on number of completed transactions, for the past 20 years.